Cancer Susceptibility for Male Breast Cancer Assessed by SNP-A Analysis and Risk Alleles of <i>TP</i>53, <i>MDM</i>2, <i>VEGF</i>, <i>VEGFR</i>1, <i>HIF</i>1<i>A</i>and <i>BRCA</i>1  

作　　者：Sarika Sharma Vasudha Sambyal Kamlesh Guleria Ruhi Kapahi Neeti Rajan Singh Mridu Manjari Sarika Sharma;Vasudha Sambyal;Kamlesh Guleria;Ruhi Kapahi;Neeti Rajan Singh;Mridu Manjari(Human Cytogenetics Laboratory, Guru Nanak Dev University, Amritsar, India;Department of Surgery, Sri Guru Ram Das Institute of Medical Sciences and Research, Amritsar, India;Department of Pathology, Sri Guru Ram Das Institute of Medical Sciences and Research, Amritsar, India)

机构地区：[1]Human Cytogenetics Laboratory, Guru Nanak Dev University, Amritsar, India [2]Department of Surgery, Sri Guru Ram Das Institute of Medical Sciences and Research, Amritsar, India [3]Department of Pathology, Sri Guru Ram Das Institute of Medical Sciences and Research, Amritsar, India

出　　处：《Advances in Breast Cancer Research》2021年第4期218-233,共16页乳腺癌（英文）

摘　　要：Male Breast Cancer (MBC) has a familial component thus identification of polymorphic risk alleles of candidate genes and/or cytogenetic anomalies may help to predict the risk for the offspring of MBC patients. The conventional metaphase cytogenetics can indicate loci that are hotspots while analysis by single nucleotide polymorphism arrays (SNP-A) can identify chromosomal </span><span style="font-family:Verdana;">defects which may play a role in the etiology of cancer. A cumulative geno</span><span style="font-family:Verdana;">type risk due to each allele of candidate genes of the signaling pathways regulating </span><i><span style="font-family:Verdana;">c</span></i><span><span style="font-family:Verdana;">-</span><i><span style="font-family:Verdana;">MYC, HIF</span></i><span style="font-family:Verdana;">1</span><i><span style="font-family:Verdana;">A</span></i></span><span style="font-family:Verdana;">, </span><i><span style="font-family:Verdana;">TP</span></i><span><span style="font-family:Verdana;">53</span><i> </i></span><span style="font-family:Verdana;">and</span><i><span style="font-family:Verdana;"> BRCA</span></i><span><span style="font-family:Verdana;">1</span><i> </i></span><span style="font-family:Verdana;">may be a factor facilitating cancer </span><span style="font-family:Verdana;">development. Cancer risk was assessed in a 35-year-old healthy son of a</span><span style="font-family:Verdana;"> 60-year-old </span><span style="font-family:Verdana;">MBC patient with a family history of cancer by metaphase cytogenetics, </span><span style="font-family:Verdana;">SNP-A </span><span><span style="font-family:Verdana;">and analysis of 25 polymorphisms in six genes</span><b><i> </i></b><i><span style="font-family:Verdana;">TP</span></i><span style="font-family:Verdana;">53, </span><i><span style="font-family:Verdana;">MDM</span></i><span style="font-family:Verdana;">2</span><i><span style="font-family:Verdana;">, VEGF,</span></i></span><i><span style="font-family:Verdana;"> VEGFR</span></i><span style="font-fMale Breast Cancer (MBC) has a familial component thus identification of polymorphic risk alleles of candidate genes and/or cytogenetic anomalies may help to predict the risk for the offspring of MBC patients. The conventional metaphase cytogenetics can indicate loci that are hotspots while analysis by single nucleotide polymorphism arrays (SNP-A) can identify chromosomal </span><span style="font-family:Verdana;">defects which may play a role in the etiology of cancer. A cumulative geno</span><span style="font-family:Verdana;">type risk due to each allele of candidate genes of the signaling pathways regulating </span><i><span style="font-family:Verdana;">c</span></i><span><span style="font-family:Verdana;">-</span><i><span style="font-family:Verdana;">MYC, HIF</span></i><span style="font-family:Verdana;">1</span><i><span style="font-family:Verdana;">A</span></i></span><span style="font-family:Verdana;">, </span><i><span style="font-family:Verdana;">TP</span></i><span><span style="font-family:Verdana;">53</span><i> </i></span><span style="font-family:Verdana;">and</span><i><span style="font-family:Verdana;"> BRCA</span></i><span><span style="font-family:Verdana;">1</span><i> </i></span><span style="font-family:Verdana;">may be a factor facilitating cancer </span><span style="font-family:Verdana;">development. Cancer risk was assessed in a 35-year-old healthy son of a</span><span style="font-family:Verdana;"> 60-year-old </span><span style="font-family:Verdana;">MBC patient with a family history of cancer by metaphase cytogenetics, </span><span style="font-family:Verdana;">SNP-A </span><span><span style="font-family:Verdana;">and analysis of 25 polymorphisms in six genes</span><b><i> </i></b><i><span style="font-family:Verdana;">TP</span></i><span style="font-family:Verdana;">53, </span><i><span style="font-family:Verdana;">MDM</span></i><span style="font-family:Verdana;">2</span><i><span style="font-family:Verdana;">, VEGF,</span></i></span><i><span style="font-family:Verdana;"> VEGFR</span></i><span style="font-f

关 键 词：Breast Cancer ANEUPLOIDY Polymorphism CN-LOH SNP-A 

分 类 号：R73[医药卫生—肿瘤]